Trivalent SARS-CoV-2 virus-like particle vaccines exhibit broad-spectrum neutralization and protection against XBB.1 and BA.2.86 variants.

Lu Zhang Siyu Tian Jun Dai Yuanyuan Li Yu Zhou Yan Li Jiao Xu Shuyun Liu Zhiwei Lin Zhaoyong Zhang Jiantao Chen Peilan Wei Jingxian Zhao Jing Jin Yanqun Wang Jincun Zhao

Virol Sin

State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, 510182, China; Guangzhou National Laboratory, Guangzhou, Guangdong, 510182, China; Shanghai Institute for Advanced Immunochemical Studies, School of Life Science and Technology, ShanghaiTech University, Shanghai, 201210, China; Institute for Hepatology, National Clinical Research Center for Infectious Disease, Shenzhen Third People's Hospital; The Second Affiliated Hospital, School of Medicine, Southern University of Science and Technology, Shenzhen, 518000, China. Electronic address:

Published: October 2024

• RBDs of the WT, BQ.1.1 and XBB.1 variants were genetically fused and displayed on the VLP to create RBDV14 M. • RBDV14 M can induce superior antibody responses against the newly emerged SARS-CoV-2 variants XBB.1, EG.5 and BA.2.86. • RBDV14 M is one of the few existing next-generation vaccine candidates that utilize virus-like particle platform.

Download full-text PDF	Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11738757	PMC
http://dx.doi.org/10.1016/j.virs.2024.08.005	DOI Listing

Publication Analysis

Top Keywords

virus-like particle

• rbdv14 m

trivalent sars-cov-2

sars-cov-2 virus-like

particle vaccines

vaccines exhibit

exhibit broad-spectrum

broad-spectrum neutralization

neutralization protection

protection xbb1

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!